Germantown, MD, United States of America

Helen Sabzevari

USPTO Granted Patents = 5 

Average Co-Inventor Count = 2.5

ph-index = 1

Forward Citations = 4(Granted Patents)


Location History:

  • Blacksburg, VA (US) (2022)
  • Germantown, MD (US) (2022 - 2024)

Company Filing History:


Years Active: 2022-2025

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Helen Sabzevari

Introduction

Helen Sabzevari is a prominent inventor based in Germantown, MD. With a robust portfolio comprising five patents, she has made significant strides in the field of cancer treatment through her innovative work. Her latest patents reflect cutting-edge advancements in the development of fusion proteins and chimeric antigen receptors.

Latest Patents

Helen's recent patents include groundbreaking inventions such as a fusion protein designed for cancer therapy. This protein comprises a component that is either an antibody or a fragment/variant thereof and a cytokine trap or adenosine deaminase. Notably, the invention encompasses embodiments where the antibody is an anti-PD-1 antibody or binds to tumor antigens, including MUC16 or MUC1. Additionally, it features a TGF-β trap, along with polynucleotides encoding the fusion protein and the method of using the composition specifically in cancer treatment. Another significant patent includes MUC16 specific chimeric antigen receptors that harness anti-MUC16 monoclonal antibodies. This invention aims to enhance cancer therapy through immune effector cells and provides methods for addressing proliferative disorders.

Career Highlights

Helen Sabzevari is a key figure at Precigen, Inc., where she drives innovation in developing therapeutic solutions for cancer. Her expertise and pioneering approach have positioned her as a leader in her field, reflecting her dedication to improving patient outcomes through her inventions.

Collaborations

Throughout her career, Helen has collaborated with notable coworkers, including Rutul R. Shah and Simon Metenou. Together, they contribute to advancing research and innovations within the company, fostering a collaborative environment that encourages groundbreaking discoveries.

Conclusion

Helen Sabzevari's contributions to cancer therapy are remarkable, showcasing her inventiveness and commitment to scientific advancement. With her latest patents and ongoing collaborations, she continues to influence the field significantly. Her work not only enhances therapeutic strategies but also inspires future innovations in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…